Showing 4171-4180 of 5957 results for "".
- OcuCell Announces Funding from the Georgia Eye Bankhttps://modernod.com/news/ocucell-announces-funding-from-the-georgia-eye-bank/2481845/OcuCell, a provider of ocular cell therapy, announce funding from the Georgia Eye Bank. Founded in 1961, Georgia Eye Bank has provided over 60,000 corneas for transplant and is dedicated to improving vision and lives through transplantation of ocular tissue and cells. Fin
- Apellis Receives Permanent J-Code for GA Drug Syfovrehttps://modernod.com/news/apellis-receives-permanent-j-code-for-ga-drug-syfovre/2481844/The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a permanent and product-specific J-code (J2781) for Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection), the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code f
- University of Toronto Researchers Build Online Glaucoma Simulatorhttps://modernod.com/news/university-of-toronto-researchers-build-online-glaucoma-simulator/2481843/Researchers at the University of Toronto have built an online simulator that is designed to give an improved visual representation of the deterioration caused by glaucoma. The simulator, built by Prof. Willy Wong and PhD candidat
- Pixium Vision Complete Reverse Stock Splithttps://modernod.com/news/pixium-vision-complete-reverse-stock-split/2481842/Pixium Vision announced the completion of a reverse stock split, as decided by its Board of Directors on July 27, 2023, on the basis of 1 new share for 50 existing shares. Shareholders who could not hold a multiple of 50 existing shares will be automatically compensated of their fractio
- Erin Powers Joins J&J Vision as Vice President of US Sales and Marketing for its Surgical Vision Portfoliohttps://modernod.com/news/erin-powers-joins-jj-vision-as-vice-president-of-us-sales-and-marketing-for-its-surgical-vision-portfolio/2481838/Johnson & Johnson announced the appointment of Erin Powers to the position of Vice President of US Sales and Marketing for its Surgical Vision portfolio. Ms. Powers will lead the US sales, marketing, and professional education teams, and will join the company within t
- Ocugen Announces Positive Update from the Phase 1/2 Trial of OCU400, a Gene Therapy Candidate for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-update-from-the-phase-12-trial-of-ocu400-a-gene-therapy-candidate-for-the-treatment-of-rp-and-lca/2481836/Ocugen announced a clinical study update for retinitis pigmentosa (RP) participants treated in the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations, and Leber congenital amaurosis (LCA) with mutation(s) in the CE
- Sight Sciences Appoints Matt Link as Chief Commercial Officerhttps://modernod.com/news/sight-sciences-appoints-matt-link-as-chief-commercial-officer/2481835/Sight Sciences announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. Mr. Link has more than 20 years of experience building teams and leading innovation in the health care and medical technology industries, most recently serving as Mana
- Altris Receives FDA Clearance of Altris IMS Platform for OCT Scan Analysishttps://modernod.com/news/altris-receives-fda-clearance-of-altris-ims-platform-for-oct-scan-analysis/2481833/Altris received FDA 510(k) clearance for the Altris IMS, the company’s image, and data management platform. The Altris platform is designed to store, organize, and support in-depth analysis of Optical Coherence Tomography (OCT) scans. The platform provides secu
- NeoLight’s Icon Go With Fluorescein Angiography Capabilities Cleared by FDA for Portable Retinal Imaginghttps://modernod.com/news/neolights-icon-go-with-fluorescein-angiography-capabilities-cleared-by-fda-for-portable-retinal-imaging/2481829/NeoLight announced FDA Class II clearance for its Icon Go portable ophthalmic retinal imaging system with expanded fluorescein angiography (FA) capabilities. The Icon Go retinal diagnostics device is designed to provide retinal imaging across diverse patient care environments
- Bausch + Lomb Launches Dry Eye Drug Miebo in the United Stateshttps://modernod.com/news/bausch-lomb-launches-dry-eye-drug-miebo-in-the-united-states/2481826/Bausch + Lomb announced the US commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). In May, Bausch + Lomb and Novaliq received FDA for Miebo as the first and only FDA-approved